Abstract: A toner comprising a toner particle comprising a binder resin and a crystalline resin, wherein the binder resin comprises an amorphous resin, when the toner is measured with a temperature-modulated differential scanning calorimeter, at least one endothermic peak derived from the crystalline resin is present in a temperature range from 55.0° C. to 95.0° C. in a total heat flow; and a ratio of an endothermic quantity of the endothermic peak in a reversing heat flow to an endothermic quantity of the endothermic peak in the total heat flow is 50.0% or more, a glass transition temperature Tg1st obtained in the reversing heat flow in a first temperature rise and a glass transition temperature Tg2nd obtained in a reversing heat flow in a second temperature rise satisfy Tg1st?Tg2nd?7.0° C.

Abstract: The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.

Abstract: The present invention provides collagen-binding agents that can be used to treat wounds, ischemic heart disease, and other conditions. The collagen-binding agents comprise a therapeutic agent, a protease cleavage site, and a collagen-binding domain. The present invention further provides pharmaceutical compositions and biomedical devices comprising the disclosed collagen-binding agents, as well as methods for treating a condition using the collagen-binding agents.

Abstract: An electrophotographic apparatus comprising an electrophotographic photosensitive member, a charging device and a developing device, wherein the charging device comprises a conductive member arranged to be capable of contacting the electrophotographic photosensitive member, a conductive layer of the conductive member comprises a matrix domain structure, at least a part of the domains Dt is exposed at the conductive member outer surface, the matrix has a volume resistivity R1 of larger than 1.00×1012 ?·cm, the domains Dt has a volume resistivity of smaller than R1, the developing device comprises the toner, domains Dc formed of the crystalline material exist in a cross section of the toner, distances between adjacent wall surfaces of the domains Dc is from 30 to 1,100 nm, and a weight-average particle diameter D4 of the toner and distances Dms between adjacent wall surfaces between the domains Dt satisfies D4?Dms.

Abstract: An electrophotographic apparatus comprising an electrophotographic photosensitive member, a charging device and a developing device, wherein the charging device comprises a conductive member arranged to be capable of contacting the electrophotographic photosensitive member, the conductive layer at the outer surface of the conductive member comprises a matrix and a plurality of domains dispersed in the matrix, at least some of the domains are exposed at the outer surface of the conductive member, the matrix has a volume resistivity R1 of larger than 1.00×1012 ?·cm, the volume resistivity R1 of the matrix is 1.0×105 times or more a volume resistivity R2 of the domains, the developing device comprises the toner comprising a toner particle and a silica fine particle, and a coverage ratio of the toner surface with the silica fine particles is from 62.0% by area to 100.0% by area as determined by X-ray photoelectron spectroscopy.

Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

Abstract: A toner comprising a toner particle comprising a binder resin and a crystalline resin, wherein the binder resin comprises an amorphous resin, when the toner is measured with a temperature-modulated differential scanning calorimeter, at least one endothermic peak derived from the crystalline resin is present in a temperature range from 55.0° C. to 95.0° C. in a total heat flow; and a ratio of an endothermic quantity of the endothermic peak in a reversing heat flow to an endothermic quantity of the endothermic peak in the total heat flow is 50.0% or more, a glass transition temperature Tg1st obtained in the reversing heat flow in a first temperature rise and a glass transition temperature Tg2nd obtained in a reversing heat flow in a second temperature rise satisfy Tg1st?Tg2nd?7.0° C.

Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

Abstract: An electrophotographic apparatus comprising an electrophotographic photosensitive member, a charging device and a developing device, wherein the charging device comprises a conductive member arranged to be capable of contacting the electrophotographic photosensitive member, the conductive layer at the outer surface of the conductive member comprises a matrix and a plurality of domains dispersed in the matrix, at least some of the domains are exposed at the outer surface of the conductive member, the matrix has a volume resistivity R1 of larger than 1.00×1012 ?·cm, the volume resistivity R1 of the matrix is 1.0×105 times or more a volume resistivity R2 of the domains, the developing device comprises the toner comprising a toner particle and a silica fine particle, and a coverage ratio of the toner surface with the silica fine particles is from 62.0% by area to 100.0% by area as determined by X-ray photoelectron spectroscopy.

Abstract: An electrophotographic apparatus comprising an electrophotographic photosensitive member, a charging device and a developing device, wherein the charging device comprises a conductive member arranged to be capable of contacting the electrophotographic photosensitive member, a conductive layer of the conductive member comprises a matrix domain structure, at least a part of the domains Dt is exposed at the conductive member outer surface, the matrix has a volume resistivity R1 of larger than 1.00×1012 ?·cm, the domains Dt has a volume resistivity of smaller than R1, the developing device comprises the toner, domains Dc formed of the crystalline material exist in a cross section of the toner, distances between adjacent wall surfaces of the domains Dc is from 30 to 1,100 nm, and a weight-average particle diameter D4 of the toner and distances Dms between adjacent wall surfaces between the domains Dt satisfies D4?Dms.

Abstract: A toner comprising a toner particle including a binder resin, wherein in a temperature T (° C.)-storage elastic modulus G? (Pa) curve obtained by measuring the toner with a rheometer, a storage elastic modulus G? (80° C.) at 80° C. is from 2.0×103 Pa to 2.0×105 Pa; and a local minimum value of a change amount (dG?/dT) of a storage elastic modulus G? in a range of 60° C. to 80° C. with respect to a temperature T is ?1.0×106 or less, and when the temperature of the toner is raised, where a projected area of the toner at 80° C. is S1 (?m2), a radius of the projected area of the toner at 80° C. is R1 (?m), and a projected area of the toner at 120° C. is S2 (?m2), the S1, R1 and S2 satisfy a following formula (1): S2/S1×1/R1?0.22.

Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

Abstract: The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.

Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

Abstract: 1) A graft material for nerve regeneration characterizing by comprising collagen-based materials containing collagen having an orientation. 2) A method for producing a graft material for nerve regeneration comprising a step of immersing the collagen-based materials containing collagen having an orientation in a solution containing a collagen-binding site-containing growth factor comprising a receptor agonist peptide and a collagen-binding peptide and binding the collagen-binding site-containing growth factor to the collagen. 3) A kit for producing a graft material for nerve regeneration characterized by comprising collagen-based materials containing collagen having an orientation, and a collagen-binding site-containing growth factor comprising a receptor agonist peptide and a collagen-binding peptide.